PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30705592-4 2019 Due to ponatinib"s unique multi-targeted characteristics, further studies have demonstrated its ability to target other important tyrosine kinases (FGFR, PDGFR, SRC, RET, KIT, and FLT1) in other human malignancies. ponatinib 7-16 ret proto-oncogene Homo sapiens 166-169 32095692-6 2020 A nicotinamide analogue of ponatinib, HSN748, retains activity against FLT3, ABL1, RET, and PDGFRalpha/beta but loses activity against c-Src and P38alpha. ponatinib 27-36 ret proto-oncogene Homo sapiens 83-86 30038711-0 2018 RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. ponatinib 69-78 ret proto-oncogene Homo sapiens 0-3 30038711-4 2018 Identifying ponatinib as the most potent RET inhibitor tested, we used ponatinib to gauge therapeutic responsiveness in RET fusion-positive patient-derived xenograft (PDX) models. ponatinib 12-21 ret proto-oncogene Homo sapiens 41-44 30038711-6 2018 By comparing ponatinib activity in RET fusion-positive and RET fusion-negative PDX models alongside a standard of care chemotherapeutic agent, we show that RET fusions in colorectal tumors are therapeutically responsive to RET inhibition. ponatinib 13-22 ret proto-oncogene Homo sapiens 35-38 28615362-4 2017 We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. ponatinib 50-59 ret proto-oncogene Homo sapiens 109-112 28500237-2 2017 Ponatinib is a multi-kinase inhibitor with low-nanomolar potency against the RET kinase domain. ponatinib 0-9 ret proto-oncogene Homo sapiens 77-80 28500237-3 2017 Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in RET fusion-positive LC-2/ad lung adenocarcinoma cells and inhibits phosphorylation of the RET fusion protein and signaling through ERK1/2 and AKT. ponatinib 26-35 ret proto-oncogene Homo sapiens 82-85 28500237-3 2017 Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in RET fusion-positive LC-2/ad lung adenocarcinoma cells and inhibits phosphorylation of the RET fusion protein and signaling through ERK1/2 and AKT. ponatinib 26-35 ret proto-oncogene Homo sapiens 172-175 29440177-4 2018 Ponatinib was tested for efficacy in two patient-derived xenograft (PDX) models and one cell-line xenograft model of SCCOHT.Results: The receptor tyrosine kinase (RTK) family was enriched in siRNA screen hits, with FGFRs and PDGFRs being overlapping hits between drug and siRNA screens. ponatinib 0-9 ret proto-oncogene Homo sapiens 137-161 29440177-4 2018 Ponatinib was tested for efficacy in two patient-derived xenograft (PDX) models and one cell-line xenograft model of SCCOHT.Results: The receptor tyrosine kinase (RTK) family was enriched in siRNA screen hits, with FGFRs and PDGFRs being overlapping hits between drug and siRNA screens. ponatinib 0-9 ret proto-oncogene Homo sapiens 163-166 29440177-6 2018 We further identified ponatinib as the most effective clinically approved RTK inhibitor. ponatinib 22-31 ret proto-oncogene Homo sapiens 74-77 28615362-4 2017 We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. ponatinib 50-59 ret proto-oncogene Homo sapiens 165-168 25122427-9 2014 Stable cells became sensitized to the RET tyrosine kinase inhibitors, vandetanib and ponatinib. ponatinib 85-94 ret proto-oncogene Homo sapiens 38-41 23526464-0 2013 Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. ponatinib 0-9 ret proto-oncogene Homo sapiens 61-64 23526464-0 2013 Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. ponatinib 11-18 ret proto-oncogene Homo sapiens 61-64 23526464-3 2013 OBJECTIVE: We tested whether ponatinib inhibited RET kinase and oncogenic activity. ponatinib 29-38 ret proto-oncogene Homo sapiens 49-52 23526464-4 2013 METHODS: Ponatinib activity was studied by an in vitro RET immunocomplex kinase assay and immunoblotting. ponatinib 9-18 ret proto-oncogene Homo sapiens 55-58 23526464-7 2013 RESULTS: Ponatinib inhibited immunopurified RET kinase at the IC50 of 25.8 nM (95% confidence interval [CI] = 23.15-28.77 nM). ponatinib 9-18 ret proto-oncogene Homo sapiens 44-47 23526464-9 2013 Ponatinib blunted phosphorylation of point-mutant and rearranged RET-derived oncoproteins and inhibited proliferation of RET-transformed fibroblasts and RET mutant thyroid carcinoma cells. ponatinib 0-9 ret proto-oncogene Homo sapiens 65-68 23526464-9 2013 Ponatinib blunted phosphorylation of point-mutant and rearranged RET-derived oncoproteins and inhibited proliferation of RET-transformed fibroblasts and RET mutant thyroid carcinoma cells. ponatinib 0-9 ret proto-oncogene Homo sapiens 121-124 23526464-9 2013 Ponatinib blunted phosphorylation of point-mutant and rearranged RET-derived oncoproteins and inhibited proliferation of RET-transformed fibroblasts and RET mutant thyroid carcinoma cells. ponatinib 0-9 ret proto-oncogene Homo sapiens 121-124 23526464-11 2013 Ponatinib-treated TT cell tumors displayed a reduction in the mitotic index, RET phosphorylation, and signaling. ponatinib 0-9 ret proto-oncogene Homo sapiens 77-80 23526464-12 2013 CONCLUSIONS: Ponatinib is a potent inhibitor of RET kinase and has promising preclinical activity in models of RET-driven medullary thyroid carcinoma. ponatinib 13-22 ret proto-oncogene Homo sapiens 48-51 23526464-12 2013 CONCLUSIONS: Ponatinib is a potent inhibitor of RET kinase and has promising preclinical activity in models of RET-driven medullary thyroid carcinoma. ponatinib 13-22 ret proto-oncogene Homo sapiens 111-114 26377589-3 2015 Several related clinical trials for non-small cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as cabozantinib, lenvatinib, vandetanib, sunitinib, ponatinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. ponatinib 189-198 ret proto-oncogene Homo sapiens 82-85